Valneva SE (NASDAQ:VALN) Short Interest Down 84.2% in February

Valneva SE (NASDAQ:VALN) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 5,800 shares, a decrease of 84.2% from the February 13th total of 36,700 shares. Based on an average trading volume of 59,500 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Valneva Trading Up 0.2 %

Shares of VALN traded up $0.02 during trading on Wednesday, reaching $7.08. 3,080 shares of the company traded hands, compared to its average volume of 25,708. The stock has a 50-day simple moving average of $5.97 and a 200-day simple moving average of $5.61. The stock has a market cap of $574.92 million, a PE ratio of -54.65 and a beta of 1.93. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.

Institutional Trading of Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in Valneva SE (NASDAQ:VALN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Valneva in a research report on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.